Bydureon

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
01220112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIMS To compare healthcare utilization and costs between patients with type 2 diabetes (T2D) treated with exenatide (Bydureon… (More)
Is this relevant?
2017
2017
BACKGROUND The aim was to investigate real-world treatment outcomes and tolerability of GLP-1 receptor agonist (GLP-1RA) therapy… (More)
Is this relevant?
2014
2014
Bydureon is a new galenic formulation (long-acting release) of exenatide, the first agonist of Glucagon-Like Peptide-1 (GLP-1… (More)
Is this relevant?
Review
2013
Review
2013
volume 31 number 6 June 2013 nature biotechnology thiazolidinediones (TZDs). NICE requested additional evidence and said it will… (More)
Is this relevant?
Review
2013
Review
2013
In April, Bristol-Myers Squibb announced plans to close down Amylin’s San Diego headquarters at the end of next year. The New… (More)
Is this relevant?
2012
2012
  • The Medical letter on drugs and therapeutics
  • 2012
 
Is this relevant?
2012
2012
  • Drug and therapeutics bulletin
  • 2012
▾Exenatide is a glucagon-like peptide 1 (GLP-1) agonist used in the management of people with type 2 diabetes. A twice-daily… (More)
Is this relevant?
Review
2012
Review
2012
According to the Centers for Disease Control and Prevention, approximately 1.9 million adults aged 20 yr and older were newly… (More)
  • figure 1
Is this relevant?
2011
2011
In May, the drugdelivery specialist Alkermes announced it would merge with Elan Drug Technologies (EDT), the chemical formulation… (More)
Is this relevant?
2011
2011
In May, the drugdelivery specialist Alkermes announced it would merge with Elan Drug Technologies (EDT), the chemical formulation… (More)
Is this relevant?